Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Liberia Ebola vaccine trial "challenging" as cases tumble

Published 24/01/2015, 15:32
Liberia Ebola vaccine trial "challenging" as cases tumble
MRCG
-
GSK
-
JNJ
-

By Ben Hirschler

DAVOS, Switzerland (Reuters) - A steep fall in Ebola cases in Liberia will make it hard to prove whether experimental vaccines work in a major clinical trial about to start in the country, the head of the U.S. National Institutes of Health (NIH) said on Saturday.

The NIH might have to move some testing to neighbouring Sierra Leone, while regulators could end up approving Ebola shots based on efficacy data from animal tests backed by only limited human evidence, Francis Collins told Reuters.

Liberia, once the epicentre of West Africa's deadly Ebola epidemic, has just five remaining confirmed cases of the disease, a senior health official has said.

The sharp decrease in cases is clearly good news, but it poses a problem for scientists from the NIH, GlaxoSmithKline and Merck, who want to enrol 27,000 people at risk of infection in the pivotal Phase III Liberian study.

"It's going to be a hard trial," Collins said on the sidelines of the World Economic Forum in Davos. "It's possible we may have to move some of the effort to Sierra Leone, which is unfortunately in not quite such a good position as Liberia."

The big Liberian trial, the first of several planned for West Africa, aims to enroll at-risk people such as healthcare staff, family members and burial workers. It will test a GSK vaccine, a rival one from Merck and NewLink, and a placebo.

"It may, at this point, be hard to find 27,000 people at risk," Collins said. "It is going to be challenging."

Nonetheless, vaccines could still be submitted to regulators using efficacy data from non-human primate experiments, plus proof of safety and immune system response in humans.

"That is the default and certainly the FDA (U.S. Food and Drug Administration) has that particular pathway available. If it is not possible to get the rigorous human data, it is still possible a vaccine could be approved," Collins said.

Healthcare experts meeting in Davos this week have stressed the need to keep up the fight against Ebola until there are zero cases in West Africa, where more than 8,600 people have died from the disease.

Jeremy Farrar, director of Britain's Wellcome Trust health charity, said vaccines and drugs were still needed for the current epidemic and to fight future ones.

Johnson & Johnson, working with Bavarian Nordic , also has an Ebola vaccine in earlier-stage clinical tests.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.